Suppr超能文献

欧洲应对甲状腺癌——挑战与机遇

Tackling Thyroid Cancer in Europe-The Challenges and Opportunities.

作者信息

Horgan Denis, Führer-Sakel Dagmar, Soares Paula, Alvarez Clara V, Fugazzola Laura, Netea-Maier Romana T, Jarzab Barbara, Kozaric Marta, Bartes Beate, Schuster-Bruce James, Dal Maso Luigino, Schlumberger Martin, Pacini Furio

机构信息

European Alliance for Personalised Medicine, 1040 Brussels, Belgium.

Department of Endocrinology, Diabetes and Metabolism, Endocrine Tumour Center at West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, 45122 Duisburg, Germany.

出版信息

Healthcare (Basel). 2022 Aug 25;10(9):1621. doi: 10.3390/healthcare10091621.

Abstract

Thyroid cancer (TC) is the most common malignancy of the endocrine system that affects the thyroid gland. It is usually treatable and, in most cases, curable. The central issues are how to improve knowledge on TC, to accurately identify cases at an early stage that can benefit from effective intervention, optimise therapy, and reduce the risk of overdiagnosis and unnecessary treatment. Questions remain about management, about treating all patients in referral centres, and about which treatment should be proposed to any individual patient and how this can be optimised. The European Alliance for Personalised Medicine (EAPM) hosted an expert panel discussion to elucidate some of the challenges, and to identify possible steps towards effective responses at the EU and member state level, particularly in the context of the opportunities in the European Union's evolving initiatives-notably its Beating Cancer Plan, its Cancer Mission, and its research funding programmes. Recommendations emerging from the panel focus on improved infrastructure and funding, and on promoting multi-stakeholder collaboration between national and European initiatives to complement, support, and mutually reinforce efforts to improve patient care.

摘要

甲状腺癌(TC)是影响甲状腺的最常见内分泌系统恶性肿瘤。它通常是可治疗的,而且在大多数情况下是可治愈的。核心问题在于如何增进对甲状腺癌的了解,如何准确早期识别可从有效干预中获益的病例,优化治疗,并降低过度诊断和不必要治疗的风险。关于管理、在转诊中心治疗所有患者、应向任何个体患者推荐何种治疗以及如何优化治疗等问题仍然存在。欧洲个性化医疗联盟(EAPM)举办了一次专家小组讨论,以阐明其中一些挑战,并确定在欧盟和成员国层面采取有效应对措施的可能步骤,特别是在欧盟不断发展的倡议所带来的机遇背景下——尤其是其《战胜癌症计划》、《癌症使命》及其研究资助计划。专家小组提出的建议侧重于改善基础设施和资金,并促进国家和欧洲倡议之间的多利益相关方合作,以补充、支持和相互加强改善患者护理的努力。

相似文献

1
Tackling Thyroid Cancer in Europe-The Challenges and Opportunities.
Healthcare (Basel). 2022 Aug 25;10(9):1621. doi: 10.3390/healthcare10091621.
3
Tackling Mantle Cell Lymphoma in Europe.
Healthcare (Basel). 2022 Sep 3;10(9):1682. doi: 10.3390/healthcare10091682.
4
Anniversary Oncology Days in Paris.
Exp Oncol. 2023 Dec 28;45(3):273-274.
5
A research roadmap for complementary and alternative medicine - what we need to know by 2020.
Forsch Komplementmed. 2014;21(2):e1-16. doi: 10.1159/000360744. Epub 2014 Mar 24.
6
How Can the EU Beating Cancer Plan Help in Tackling Lung Cancer, Colorectal Cancer, Breast Cancer and Melanoma?
Healthcare (Basel). 2022 Aug 25;10(9):1618. doi: 10.3390/healthcare10091618.
7
Accelerating the Development and Validation of Liquid Biopsy for Early Cancer Screening and Treatment Tailoring.
Healthcare (Basel). 2022 Sep 7;10(9):1714. doi: 10.3390/healthcare10091714.
8
The future of Cochrane Neonatal.
Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12.

引用本文的文献

1
Molecular predictive biomarker testing in advanced thyroid cancer - a European consensus.
Eur Thyroid J. 2025 Jul 7;14(4). doi: 10.1530/ETJ-25-0024. Print 2025 Aug 1.
3
Global burden of thyroid cancer among adolescents and young adults, 1990-2021, and projections to 2050: an analysis based on the GBD 2021.
Front Endocrinol (Lausanne). 2025 Apr 14;16:1503144. doi: 10.3389/fendo.2025.1503144. eCollection 2025.
5
Consensus Statement: Recommendations on Actionable Biomarker Testing for Thyroid Cancer Management.
Endocr Pathol. 2024 Dec;35(4):293-308. doi: 10.1007/s12022-024-09836-x. Epub 2024 Nov 23.
6
Understanding the factors of wearable devices among the patients with thyroid cancer: A modified UTAUT2 model.
PLoS One. 2024 Jul 26;19(7):e0305944. doi: 10.1371/journal.pone.0305944. eCollection 2024.
7
Current landscape and support for practical initiation of oncological prehabilitation translatable to thyroid cancer: A position paper.
Heliyon. 2024 May 11;10(10):e30723. doi: 10.1016/j.heliyon.2024.e30723. eCollection 2024 May 30.
8
Improved guidance is needed to optimise diagnostics and treatment of patients with thyroid cancer in Europe.
Endocrine. 2024 Mar;83(3):585-593. doi: 10.1007/s12020-023-03610-5. Epub 2023 Nov 25.

本文引用的文献

3
ESMO Clinical Practice Guideline update on the use of systemic therapy in advanced thyroid cancer.
Ann Oncol. 2022 Jul;33(7):674-684. doi: 10.1016/j.annonc.2022.04.009. Epub 2022 Apr 28.
4
The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020.
Lancet Diabetes Endocrinol. 2022 Apr;10(4):264-272. doi: 10.1016/S2213-8587(22)00035-3. Epub 2022 Mar 7.
5
Thyroidectomies in Italy: A Population-Based National Analysis from 2001 to 2018.
Thyroid. 2022 Mar;32(3):263-272. doi: 10.1089/thy.2021.0531.
6
Kinase Inhibitors in the Treatment of Thyroid Cancer: Institutional Experience.
Acta Clin Croat. 2020 Jun;59(Suppl 1):73-80. doi: 10.20471/acc.2020.59.s1.09.
7
The utility of ThyroSeq in the management of indeterminate thyroid nodules by fine-needle aspiration.
Cytopathology. 2021 Jul;32(4):505-512. doi: 10.1111/cyt.12981. Epub 2021 Apr 29.
8
Bringing Greater Accuracy to Europe's Healthcare Systems: The Unexploited Potential of Biomarker Testing in Oncology.
Biomed Hub. 2020 Sep 14;5(3):182-223. doi: 10.1159/000511209. eCollection 2020 Sep-Dec.
9
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
10
Radiation Exposure to the Thyroid After the Chernobyl Accident.
Front Endocrinol (Lausanne). 2021 Jan 5;11:569041. doi: 10.3389/fendo.2020.569041. eCollection 2020.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验